发布求助
文献互助 智能选刊 最新文献

Clinical Lymphoma, Myeloma & Leukemia最新文献

筛选
英文 中文
OA-10 Impaired Membrane Trafficking of GPRC5D Mediates Resistance to Anti-GPRC5D TCE OA-10 GPRC5D 的膜运输受损介导了对抗肿瘤药物 GPRC5D TCE 的耐药性
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01851-2
{"title":"OA-10 Impaired Membrane Trafficking of GPRC5D Mediates Resistance to Anti-GPRC5D TCE","authors":"","doi":"10.1016/S2152-2650(24)01851-2","DOIUrl":"10.1016/S2152-2650(24)01851-2","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-021 A German Multicenter Real-World Analysis of Talquetamab in 102 Patients With Relapsed/Refractory Multiple Myeloma P-021 Talquetamab 在 102 例复发性/难治性多发性骨髓瘤患者中的德国多中心实际应用分析
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01924-4
{"title":"P-021 A German Multicenter Real-World Analysis of Talquetamab in 102 Patients With Relapsed/Refractory Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01924-4","DOIUrl":"10.1016/S2152-2650(24)01924-4","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-34 HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma 治疗复发性/难治性多发性骨髓瘤的抗 BCMA 嵌合抗原受体 T 细胞 (CART) OA-34 HBI0101
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01875-5
{"title":"OA-34 HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01875-5","DOIUrl":"10.1016/S2152-2650(24)01875-5","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-36 METTL14 Enhances Multiple Myeloma Progression via m6A RNA Methylation-Mediated Regulation of TRAF6 Translation OA-36 METTL14通过m6A RNA甲基化介导的TRAF6翻译调控促进多发性骨髓瘤进展
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01877-9
{"title":"OA-36 METTL14 Enhances Multiple Myeloma Progression via m6A RNA Methylation-Mediated Regulation of TRAF6 Translation","authors":"","doi":"10.1016/S2152-2650(24)01877-9","DOIUrl":"10.1016/S2152-2650(24)01877-9","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-53 Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma – 4-Year-Follow-Up from the GMMG-CONCEPT trial OA-53 Isa-KRd 在高风险新诊断多发性骨髓瘤中的应用--GMMG-CONCEPT 试验的 4 年随访结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01894-9
{"title":"OA-53 Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma – 4-Year-Follow-Up from the GMMG-CONCEPT trial","authors":"","doi":"10.1016/S2152-2650(24)01894-9","DOIUrl":"10.1016/S2152-2650(24)01894-9","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142309743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-017 Impact of Genetic Ancestry on Outcomes and Toxicity of Ide-cel in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) P-017 遗传血统对复发性/难治性多发性骨髓瘤（RRMM）患者服用伊达凯（Ide-cel）治疗效果和毒性的影响
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01920-7
{"title":"P-017 Impact of Genetic Ancestry on Outcomes and Toxicity of Ide-cel in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)","authors":"","doi":"10.1016/S2152-2650(24)01920-7","DOIUrl":"10.1016/S2152-2650(24)01920-7","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-22 A Single-Cell Atlas of Bone Marrow Immune Microenvironment Characterizes Dysregulation Associated With Multiple Myeloma Outcomes OA-22 骨髓免疫微环境单细胞图谱描述了与多发性骨髓瘤结局相关的失调特征
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01863-9
{"title":"OA-22 A Single-Cell Atlas of Bone Marrow Immune Microenvironment Characterizes Dysregulation Associated With Multiple Myeloma Outcomes","authors":"","doi":"10.1016/S2152-2650(24)01863-9","DOIUrl":"10.1016/S2152-2650(24)01863-9","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142309739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-44 Frontline Systemic Treatment Outcomes in POEMS Syndrome – Analysis from the UCLH POEMS Centre Registry Spanning 25 Years OA-44 POEMS 综合征的前线系统治疗结果--来自 UCLH POEMS 中心长达 25 年的登记分析
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01885-8
{"title":"OA-44 Frontline Systemic Treatment Outcomes in POEMS Syndrome – Analysis from the UCLH POEMS Centre Registry Spanning 25 Years","authors":"","doi":"10.1016/S2152-2650(24)01885-8","DOIUrl":"10.1016/S2152-2650(24)01885-8","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-43 Interim Results of a Phase 2 Trial of Isatuximab-Lenalidomide for Patients with High-Risk Smoldering Multiple Myeloma 伊沙妥昔单抗-来那度胺治疗高危烟雾型多发性骨髓瘤患者2期试验的OA-43中期结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01884-6
{"title":"OA-43 Interim Results of a Phase 2 Trial of Isatuximab-Lenalidomide for Patients with High-Risk Smoldering Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01884-6","DOIUrl":"10.1016/S2152-2650(24)01884-6","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-47 Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) and DARA Maintenance in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) Update OA-47达拉单抗（DARA）+硼替佐米/他利度胺/地塞米松（D-VTd）和DARA维持治疗符合移植条件的新诊断多发性骨髓瘤（NDMM）：CASSIOPEIA最小残留病灶（MRD）最新进展
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01888-3
{"title":"OA-47 Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) and DARA Maintenance in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): CASSIOPEIA Minimal Residual Disease (MRD) Update","authors":"","doi":"10.1016/S2152-2650(24)01888-3","DOIUrl":"10.1016/S2152-2650(24)01888-3","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信